AzTrials
AzTrials

EndometriosisPhase 4NCT06577233

Superior Hypogastric Nerve Plexus Block With Bupivacaine After Robotic Resection of Endometriosis

A Phase 4 study testing Bupivacaine Hydrochloride and Normal saline in people with Endometriosis, run by Baylor College of Medicine at 1 site in United States.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Endometriosis is a condition that causes significant pelvic pain and affects 10-15% of reproductive age women. Treatment options area both medical and surgical for pain relief, however with surgical options, past studies have demonstrated a higher risk of surgical complications as well as higher postoperative pain… Read more about this study

Who is it for?
Ages 18 to 65 years, women onlyHealthy volunteers can take part
Conditions the study is for
Endometriosis
What is being tested?
Bupivacaine Hydrochloride and Normal saline
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
60 participants
Where
1 siteUnited States
Study dates
28 Aug 2024to 31 Aug 2025
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • 18-65 years old
  • Scheduled to undergo a robotic assisted resection of endometriosis

Who cannot join

  • Subjects who are part of a vulnerable population will be excluded including those who are prisoners, younger than 18 years old, pregnant, individuals with mental disabilities or cognitive impairment.

Trial locations and contacts

1 site in 1 country.

Ann Tims contact

8328267464

atims@bcm.edu

United States1 site, 1 recruiting
  • Texas Childrens Hospital Pavilion for Women

    Houston, Texas, 77030

    Xiaoming Guan, PhD, MD, 973-330-2602, guanxiaoming@yahoo.com

    Xiaoming Guan, PhD, MD

    Recruiting

Other trials in United States

About this study

Official title: Superior Hypogastric Nerve Plexus Block With Bupivacaine for Postoperative Pain Reduction Following Robotic Assisted Resection of Endometriosis: A Randomized Control Trial

Endometriosis is a condition that causes significant pelvic pain and affects 10-15% of reproductive age women. Treatment options area both medical and surgical for pain relief, however with surgical options, past studies have demonstrated a higher risk of surgical complications as well as higher postoperative pain scores in women with endometriosis. Despite attempts to limit narcotic pain medications with enhanced recovery after surgery (ERAS) protocols, persistent opioid use after surgery is a national crisis, and it is important to explore multimodal options for pain relief. Various studies have shown improvement in pain with use of superior hypogastric nerve blocks in gynecologic surgery, but these effects have not yet been examined in the setting of a minimally invasive endometriosis resection.

The goal of this clinical trial is to determine if a superior hypogastric nerve plexus block with 0.25% bupivacaine hydrochloride can decrease postoperative pain and opioid requirements in patients undergoing robotic assisted resection of endometriosis for the first week after surgery.

Read more

Researchers will perform a superior hypogastric nerve plexus block by either injecting 0.25% bupivacaine hydrochloride (investigative treatment) or normal saline (placebo) in subjects who are undergoing a robotic assisted resection of endometriosis.

To determine if postoperative pain is reduced, the subject will be asked to rate their pain score on the Visual Analog Scale (VAS) at 0 hours, 2 hours and 4 hours postop while in the Post-anesthesia Care Unit (PACU). They will then document their pain score each day on a form provided to them for 7 days after surgery.

To determine the effect of this research study on postoperative opioid requirements, the subject will be asked to fill out a form documenting how many tablets of an opioid medication they took each day for a total of 7 days after surgery.

Read the detailed description

This clinical study will recruit patients at their preoperative visit. If the surgery is Davinci single incision laparoscopic surgery (or single incision plus one port) for resection endometriosis, the subject will be informed about the clinical trial, as well as risks and benefits of enrolling by the fellow or attending surgeon. The pre-op visit is typically 1-4 weeks before the day of surgery. They can make the decision either the day of the pre-op visit or they can have time to consider it and inform us of their decision on the day of surgery. If they agree to participate in the trial, they will be consented for the procedure and for enrollment in the trial. The subjects that agree will be assigned a number to de-identify data and then randomly assigned to the placebo or interventional treatment group with use of a computer generator (RedCap). The clinician will be aware of the group that they are in but the subject will not be aware of the group assignment.

At the time of enrollment the subject will also be informed that their medical record will be accessed to obtain information from the surgery and demographics. They will be informed that this information will be de-identified and entered into a password protected database called RedCap. The subject information obtained that will be demographics including those obtained from their pre-operative visit clinic note such as: age, race and ethnicity, gravidity/parity, surgical history, preoperative visual analog scale (VAS) score. As well as the information obtained from the operative note: stage of endometriosis diagnosed, additional laparoscopic procedures performed during the surgery, operative time, estimated blood loss, major intraoperative complication, uterine weight, and pathology. Their medical records will be reviewed by members of the surgical team at the time of surgery, at their postoperative visit, and during data analysis, so three times total.

During the case, The trocar used for the robotic single site surgery is the Single-Site port with curved cannulas made for the DaVinci XI single site instruments. This is inserted through one incision in the umbilicus. If the patient has severe endometriosis, a right lower quadrant 8mm trocar is inserted. This is standard of care for robotic assisted single site resection of endometriosis.

For the block portion of the study, the placebo group will have 5cc of 0.9% normal saline injected superficially into the retroperitoneal space overlying the superior hypogastric nerve plexus just distal to the common iliac bifurcation, bilaterally (10cc normal saline total). The nerve plexus bifurcation will be identified by the sacral promontory and the injection region will be approximately 1-2cm below this area bilaterally. The interventional treatment group will have 5cc total of diluted 0.25% bupivacaine hydrochloride injected at the same location (10cc total).

We will perform the superior hypogastric nerve block with 10cc of 0.25% Bupivacaine Hydrochloride as this is the most common analgesic used for this block. Bupivacaine Hydrochloride is FDA approved for subcutaneous nerve blocks at concentrations of 0.25% and 0.50%. The Texas Children's Hospital Pharmacy is familiar with 0.25% Bupivacaine Hydrochloride as it is a commonly used medication in the operating room and is already present in the endometriosis resection set as it is typically injected in the incision sites after the surgery. The subject will be blinded to the group they are randomized to (either placebo or investigative treatment), but the operating room nurses and physicians will not be blinded. The surgical team will look at what group the subject is assigned to before the case and either ask for the nurse to get the 0.25% Bupivacaine Hydrochloride or a saline filled 10cc syringe. If they are In the 0.25% Bupivacaine Hydrochloride group, no additional medication will be ordered as it is already in the set.

With current endometriosis resection surgeries, 0.25% bupivacaine hydrochloride is used as local anesthetic at skin incisions and is part of the standard surgery bundle. The nerve block will be performed with instruments already in the surgery set and this will not be billed as a separate procedure. Thus, this block and the bupivacaine hydrochloride will not be expected to add to the cost of the surgery and the subject will not be charged.

The standard of care for endometriosis resection surgeries is no nerve block and to send the patient home with Ibuprofen, Tylenol and Oxycodone. The investigational treatment in this study will be to perform the nerve block, they will still go home with the same pain medications of Ibuprofen, Tylenol and Oxycodone with the same amount of pills prescribed.

To keep data safe and subject information protected, any physical data will be stored in a locked cabinet in the PI's office in Pavilion for Women. Subjects will be assigned numbers as participants so that all data can be de-identified. Electronic data will be kept in an online, password protected database (RedCap), This information will be de-identified and stored in Red-Cap, a web-based database that is password protected. As the information being put into Red-Cap will be de-identified, the information will be unable to be traced through the database. This will be secure as only the direct members of the research team will have access to this information. Red-Cap is a database that is useful to research studies as information does not need to be downloaded to specific computers or stored on external hard drives. By insuring the patient information is de-identified and untraceable before entering it into RedCap, it helps keep the data in one place password protected, therefore reducing the risks associated with losing external hard drives or personal computers.

The sample size was calculated by a Baylor College of Medicine Statistician. The proposed sample size will include 60 subjects from Texas Children's Hospital, with 30 subjects randomized to each arm. This was calculated to detect a 38% decrease in the proportion of subjects with VAS scores > 4 in the 2 hours post-op at the 95% confidence level with a power of 80%, which would come out to 25 subjects per group for a total of 50 subjects. We plan to add 20% to account for drop out rate, for a final number of 60 subjects (30 per group).

For statistical analysis, primary analysis includes comparing the Visual Analog Scale (VAS) pain levels at 2 hours, 4 hours and daily for 1 week after surgery between the placebo and the treatment group. This would be a comparison of means (mean VAS pain level score at each time in the placebo vs treatment group).

Secondary analysis includes calculating the amount of narcotic pain medications used in the first 24 hours and first week after surgery in morphine milligram equivalents and comparing that number between the placebo and treatment group. This would be a comparison of means (mean amount of narcotic pain medications in morphine milligram equivalents in the placebo vs treatment groups).

In order to reduce missing data or the subject not filling out the form, the Fellow surgeon will call the subject 7 days after surgery with a reminder to complete the form. If they do not do this, they will be excluded from the study.

Conditions
Endometriosis
Being tested
Bupivacaine Hydrochloride, Normal saline
Keywords
Endometriosis, Postoperative Pain, Robotic Surgery
Medical subject headings
Endometriosis, Pain, Postoperative

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Bupivacaine HydrochlorideDrug

    Also called Marcaine

    10cc of 0.25% Bupivacaine Hydrochloride will be injected into the peritoneum overlying the superior hypogastric nerve plexus with a laparoscopic needle during robotic surgery

  • Normal salineDrug

    Also called 0.9% Normal Saline

    10cc of 0.9% normal saline will be injected into the peritoneum overlying the superior hypogastric nerve plexus with a laparoscopic needle during robotic surgery

Study groups in NCT06577233
Study groupRoleWhat they receive
Investigative TreatmentExperimentalDuring the surgery, the investigative treatment group will have 5cc of diluted 0.25% Bupivacaine Hydrochloride injected into the superficial retroperitoneal area over the superior hypogastric nerve plexus.
Receives: Drug: Bupivacaine Hydrochloride
PlaceboPlacebo comparatorDuring the surgery, the placebo group will have 5cc of 0.9% normal saline injected into the superficial retroperitoneal area over the superior hypogastric nerve plexus.
Receives: Drug: Normal saline

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Postoperative pain

    Postoperative pain levels as characterized by the Visual Analog Scale (VAS)

    Measured: Postoperative pain level documented at 0, 2 and 4 hours after surgery, then once a day for 7 days after surgery.

Secondary outcomes (1)
  1. Opioid use

    The amount of opioid medication used in the immediate postoperative period in morphine milligram equivalents

    Measured: The first 7 days after surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Aug 2024
  2. Study start28 Aug 2024
  3. Primary completion30 Apr 2025
  4. Study completion31 Aug 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
This study will be a randomized single blind clinical trial where the participant will be blinded to whether they received a superior hypogastric nerve block with 0.25% Bupivacaine Hydrochloride (investigative treatment) or 0.9% normal saline (placebo). The researcher will not be blinded and will know which arm the participant has been randomized to. Randomization will be performed by a computer generator in RedCap.
Masking
Single blind
Who is masked
Participant
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06577233
Sponsor's protocol ID
H-55139
Status last verified
Aug 2024
First submitted
27 Aug 2024
Last updated
18 Aug 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Publications

  • Parasar P, Ozcan P, Terry KL. Endometriosis: Epidemiology, Diagnosis and Clinical Management. Curr Obstet Gynecol Rep. 2017 Mar;6(1):34-41. doi: 10.1007/s13669-017-0187-1. Epub 2017 Jan 27.

    PubMed 29276652
  • Brunes M, Johannesson U, Habel H, Forsgren C, Moawad G, Ek M. Peri- and postoperative outcomes in patients with endometriosis undergoing hysterectomy. Eur J Obstet Gynecol Reprod Biol. 2022 May;272:104-109. doi: 10.1016/j.ejogrb.2022.02.180. Epub 2022 Mar 9.

    PubMed 35299012
  • Kanellos P, Nirgianakis K, Siegenthaler F, Vetter C, Mueller MD, Imboden S. Postoperative Pain Is Driven by Preoperative Pain, Not by Endometriosis. J Clin Med. 2021 Oct 15;10(20):4727. doi: 10.3390/jcm10204727.

    PubMed 34682850
  • Meyer LA, Lasala J, Iniesta MD, Nick AM, Munsell MF, Shi Q, Wang XS, Cain KE, Lu KH, Ramirez PT. Effect of an Enhanced Recovery After Surgery Program on Opioid Use and Patient-Reported Outcomes. Obstet Gynecol. 2018 Aug;132(2):281-290. doi: 10.1097/AOG.0000000000002735.

    PubMed 29995737
  • Aytuluk HG, Kale A, Astepe BS, Basol G, Balci C, Colak T. Superior Hypogastric Plexus Blocks for Postoperative Pain Management in Abdominal Hysterectomies. Clin J Pain. 2020 Jan;36(1):41-46. doi: 10.1097/AJP.0000000000000767.

    PubMed 31567396
  • De Silva P, Daniels S, Bukhari ME, Choi S, Liew A, Rosen DMB, Conrad D, Cario GM, Chou D. Superior Hypogastric Plexus Nerve Block in Minimally Invasive Gynecology: A Randomized Controlled Trial. J Minim Invasive Gynecol. 2022 Jan;29(1):94-102. doi: 10.1016/j.jmig.2021.06.017. Epub 2021 Jun 29.

    PubMed 34197956

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Bupivacaine Hydrochloride and Normal saline in people with Endometriosis, run by Baylor College of Medicine at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 18 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Ann Tims (8328267464, atims@bcm.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Postoperative pain (time frame: Postoperative pain level documented at 0, 2 and 4 hours after surgery, then once a day for 7 days after surgery.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06577233, which also lists 6 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Aug 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in